OM:BIOA BBiotechs
BioArctic (OM:BIOA B) Could Be 8% Overvalued On Eli Lilly Collaboration Deal
BioArctic (OM:BIOA B) has attracted fresh investor attention after signing a research and collaboration agreement with Eli Lilly that centers on its BrainTransporter technology and a Lilly neurodegeneration drug candidate.
See our latest analysis for BioArctic.
The Eli Lilly agreement arrives after a year in which BioArctic’s share price return has been mixed over shorter periods but supported by strong momentum over 12 months, with a 1-year total shareholder return of 86.25% and a 5-year...